10 Best Performing Affordable Stocks Under $40

​7. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Price: $39.96

Forward P/E Ratio: 6.00

6-month Performance: 106.51%

Number of Hedge Fund Holders: 23

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the Best Performing Affordable Stocks Under $40. On January 12, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its preliminary results for the fourth quarter of 2025 and also provided its 2026 outlook.

​Although the company is set to release its official results on March 3, the preliminary data suggests that the fourth quarter revenue will be around $69.8 million, compared to $57.6 million for the same period of 2024. Moreover, management expects fourth quarter 2025 gross product sales of $84.5 million, driven by TAVALISSE net product sales of $45.6 million, GAVRETO net product sales of $10.2 million, and REZLIDHIA net product sales of $9.6 million.

For the full year, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) expects to deliver around $294.3 million in revenue, up from $179.3 million in 2024. Looking ahead, management projects 2026 total revenue in the range of $275 million to $290 million.

​That said, Wall Street is bullish on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) after the release. On January 13, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock with a $57 price target.

​Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotechnology company that discovers and develops targeted, novel drugs in oncology, immunology, and immune oncology. Its product portfolio includes Tavalisse, Fostamatinib, and R835.